The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation

Expert Opinion on Biological Therapy

Volumn 11, Issue 6, 2011, Pages 687-697

  Busca, Alessandro ^a  

^a AOU San Giovanni Battista   (Italy)

Author keywords

graft versus host disease; immunosuppression; monoclonal antibodies; stem cell transplantation

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CD20 ANTIBODY; CD3 ANTIBODY; DACLIZUMAB; ETANERCEPT; INFLIXIMAB; INOLIMOMAB; INTERLEUKIN 1; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VISILIZUMAB;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; BACTERIAL ARTHRITIS; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CHRONIC GRAFT VERSUS HOST DISEASE; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; GRAFT VERSUS HOST REACTION; HERPES ZOSTER; HUMAN; INFECTION; INFECTION COMPLICATION; INFECTIOUS COMPLICATION; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MYCOSIS; NONHUMAN; PATHOPHYSIOLOGY; PNEUMONIA; REVIEW; SEPSIS; SINGLE DRUG DOSE; SURVIVAL TIME; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; GRAFT VS HOST DISEASE; HUMANS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 79955833138     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.566852     Document Type: Review

References (69)

1. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990;75:1024-30 (Pubitemid 20067206)
2. Filipovich AH, Weisdorf D, Pavletic S, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report. Biol Blood Marrow Transpl 2005;11:945-55
3. Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002;100:415-19 (Pubitemid 34761101)
4. MacMillan ML, Weisdorf DJ, Wagner JE, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002;8:387-94
5. Basara N, Kiehl MG, Blau W, et al. Mycophenolate Mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience. Transplant Proc 2001;33:2121-3 (Pubitemid 33762653)
6. Hoda D, Pidala J, Salgado-Vila N, et al. Sirolimus for treatment of steroid-refractory acute graft-versushost disease. Bone Marrow Transplant 2010;45:1347-51
7. Remberger M, Aschan J, Barkholt L, et al. Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. Clin Transplant 2001;15:147-53 (Pubitemid 32487439)
8. Bolanos-Meade J, Jacobsohn DA, Margolis J, et al. Pentostatin in steroid-refractory acute graft-versushost disease. J Clin Oncol 2005;23:2661-8 (Pubitemid 46179455)
9. Alousi AM, Weisdorf DJ, Logan BR, et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009;114:511-17
10. Ferrara JLM, Deeg HJ. Graft-versushost disease. New Engl J Med 1991;324:667-74
11. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999;285:412-15 (Pubitemid 29343964)
12. Korngold R, Marini JC, de Baca ME, et al. Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. Biol Blood Marrow Transplant 2003;9:292-303 (Pubitemid 38351814)
13. Patriarca F, Sperotto A, Damiani D, et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 2004;89:1352-9 (Pubitemid 39540573)
14. Couriel DR, Saliba R, de Lima M, et al. A Phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009;15:1555-62
15. Marty FM, Lee SJ, Fahey MM, et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003;102:2768-76 (Pubitemid 37258330)
16. Busca A, Locatelli F, Marmont F, et al. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007;82:45-52 (Pubitemid 46033391)
17. Uberti JP, Ayash L, Ratanatharathorn V, et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transpl 2005;11:680-7 (Pubitemid 41194976)
18. Levine JE, Paczesny S, Mineishi S, et al. Etanercept plus methylprednilosone as initial therapy for acute graft-versus-host disease. Blood 2008;111:2470-5 (Pubitemid 351451462)
19. Ferrara JLM. Novel strategies for the treatment and diagnosis of graft-versushost- disease. Best Pract Clin Haematol 2007;20:91-7
20. Antin JH, Weisdorf D, Neuberg D, et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 2002;100:3479-83 (Pubitemid 35303912)
21. Gesbert F, Delespine-Carmagnat M, Bertoglio J. Recent advances in the understanding of interleukin-2 signal transduction. J Clin Immunol 1998;18:307-20 (Pubitemid 28467548)
22. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998;338:161-5 (Pubitemid 28041863)
23. Kovarik J, Wolf P, Cisterne JM, et al. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation 1997;64:1701-5 (Pubitemid 28041703)
24. Pinana JL, Valcarcel D, Martino R, et al. Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2006;12:1135-41, Erratum in: Biol Blood Marrow Transplant 2007;13:124 (Pubitemid 44660853)
25. Anasetti C, Hansen JA, Waldmann TA, et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 1994;84:1320-7 (Pubitemid 24245902)
26. Przepiorka D, Kernan NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000;95:83-9 (Pubitemid 30017229)
27. Srinivasan R, Chakrabarti S, Walsh T, et al. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol 2004;124:777-86 (Pubitemid 38365783)
28. Lee SJ, Zahrieh D, Agura E, et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004;104:1559-64 (Pubitemid 39166538)
29. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003;9:1144-50 (Pubitemid 37173698)
30. Bordigoni P, Dimicoli S, Clement L, et al. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. Br J Haematol 2006;135:382-5 (Pubitemid 44484847)
31. Rao K, Rao A, Karlsson H, et al. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease. J Pediatr Hematol Oncol 2009;31:456-61
32. Anasetti C, Lin A, Nadamanee A, et al. A phase II/III randomized, double-blind, placebo-controlled multicenter trial of humanized anti-tac for prevention of acute graft-versus-host disease (GVHD) in recipients of marrow transplants from unrelated donors. Blood 1996;88:621a
33. Blaise D, Olive D, Hirn M, et al. Prevention of acute GVHD by in vivo use of anti-interleukin-2 receptor monoclonal antibody (33B3.1): a feasibility trial in 15 patients. Bone Marrow Transplant 1991;8:105-11
34. Schmidt-Hieber M, Fietz T, Knauf W, et al. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. Br J Haematol 2005;130:568-74 (Pubitemid 43899761)
35. Massenkeil G, Rackwitz S, Genvresse I, et al. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2002;30:899-903 (Pubitemid 36097479)
36. Funke VA, de Medeiros CR, Setubal DC, et al. Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist. Bone Marrow Transplant 2006;37:961-5 (Pubitemid 43792557)
37. Pinana JL, Valcarcel D, Martino R, et al. Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2006;12:1135-41 (Pubitemid 44660853)
38. Bay JO, Dhedin N, Goerner M, et al. Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies. Transplantation 2005;80:782-8 (Pubitemid 41443760)
39. Carpenter PA, Appelbaum FR, Corey L, et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 2002;99:2712-19 (Pubitemid 34525356)
40. Carpenter PA, Lowder J, Johnston L, et al. A Phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2005;11:465-71 (Pubitemid 40753799)
41. Wandroo F, Auguston B, Cook M, et al. Successful use of Campath-1H in the treatment of steroid refractory liver GvHD. Bone Marrow Transplant 2004;34:285-7 (Pubitemid 39136842)
42. Carella AM, Beltrami G, Scalzulli PR, et al. Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD). Bone Marrow Transplant 2004;33:131-2 (Pubitemid 38159720)
43. Busca A, Locatelli F, Lovisone E, et al. Treatment of severe refractory acute graft-versus-host disease of the gastrointestinal tract with Campath-1H. Biol Blood Marrow Transplant 2005;11:734-6 (Pubitemid 41194983)
44. Schnitzler M, Hasskarl J, Egger M, et al. Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab. Biol Blood Marrow Transplant 2009;15:910-18
45. Gomez-Almaguer D, Ruiz-Arguelles GJ, del Carmen Tarin-Arzaga L, et al. Alemtuzumab for the treatment of steroidrefractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2008;14:10-5 (Pubitemid 350286746)
46. Martinez C, Solano C, Ferra C, et al. Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a Phase II study. Biol Blood Marrow Transplant 2009;15:639-42
47. Schub N, Gunther A, Schrauder A, et al. Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective. Bone Marrow Transplant 2011;46:143-7
48. Arai S, Margolis J, Zahurak M, et al. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002;8:155-60 (Pubitemid 34285074)
49. Dugan MJ, DeFor TE, Steinbuch M, et al. ATG plus corticosteroid therapy for acute graftversus- host disease: predictors of response and survival. Ann Hematol 1997;75:41-6 (Pubitemid 27379698)
50. Khoury H, Kashyap A, Adkins DR, et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 2001;27:1059-64 (Pubitemid 32591189)
51. MacMillan ML, Weisdorf DJ, Davies SM, et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2002;8:40-6
52. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991;77:1821-8
53. Remberger M, Aschan J, Barkholt L, et al. Treatment of severe acute graft-versus-host disease with antithymocyte globulin. Clin Transplant 2001;15:147-53 (Pubitemid 32487439)
54. Van Lint MT, Milone G, Leotta S, et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day + 5 responders and no advantage for nonresponders receiving antithymocyte globulin. Blood 2006;107:4177-81 (Pubitemid 43726830)
55. Lopez M, Clarkson MR, Albin M, et al. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 2006;17:2844-53 (Pubitemid 44484674)
56. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005;105:2973-8 (Pubitemid 40446295)
57. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006;108:756-62 (Pubitemid 44061381)
58. Okamoto M, Okano A, Akamatsu S, et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia 2006;20:172-3
59. Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, et al. Anti-CD20 monoclonal antibody treatment in 6 patients withtherapy-refractory chronic graft-versus-host disease. Blood 2004;104:2603-6 (Pubitemid 39331867)
60. Zaja F, Bacigalupo A, Patriarca F, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 2007;40:273-7 (Pubitemid 47108472)
61. Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, et al. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant 2009;15:1005-13
62. von Bonin M, Oelschlägel U, Radke J, et al. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation 2008;86:875-9
63. Kim SJ, Lee JW, Jung CW, et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective multicenter phase II study. Haematologica 2010;95:1935-42
64. Couriel D, Saliba R, Hicks K, et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004;104:649-54 (Pubitemid 38970556)
65. Pidala J, Kim J, Field T, et al. Infliximab for managing steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2009;15:1116-21
66. Wolff D, Roessler V, Steiner B, et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant 2005;35:1003-10 (Pubitemid 40711838)
67. Jackson K, Curlay C, Leach J, et al. Alemtuzumab as salvage therapy for steroid and ATG/etanercept-refractory acute GVHD. Bone Marrow Transplant 2011 [Epub ahead of print]
68. Ratanatharathorn V, Ayash L, Reynolds C, et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marr Transplant 2003;9:505-11 (Pubitemid 38351794)
69. Mohty M, Marchetti M, El-Cheikh J, et al. Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplant 2008;41:909-11 (Pubitemid 351761695)